Klaudia Warzycka, Karolina Maliszewska, Kinga Woźniak, Monika Gardian-Baj, Magdalena Jung, Patryk Hedesz, Maximilian Jung, Aleksandra Doryń, Krystian Jędral, Aleksandra Włodarczyk, Alicja Szczerbiak
{"title":"Anticoagulants - The Past, The Present, The Future - A Systematic Review","authors":"Klaudia Warzycka, Karolina Maliszewska, Kinga Woźniak, Monika Gardian-Baj, Magdalena Jung, Patryk Hedesz, Maximilian Jung, Aleksandra Doryń, Krystian Jędral, Aleksandra Włodarczyk, Alicja Szczerbiak","doi":"10.12775/jehs.2024.68.49539","DOIUrl":null,"url":null,"abstract":"Introduction: Anticoagulants have been discovered and developed over past 100 years. At the beginning unfractionated heparin found its applications, just later to fade into the background of newer and more effective drugs. Patients have been treated with more progressive medications – Low-Molecule-Weight Heparin (LMWH), Vitamin K Antagonists (VKA) and Novel Oral Anticoagulants (NOAC). As for today, deemed a turning point in anticoagulant therapy are inhibitors of factor XI. It is a ground-breaking innovation as it ensures high prevention of thrombotic episodes and guarantees intact physiological hemostasis.Current State of Knowledge: The coagulation cascade and molecules part taking in that have been discovered and described extensively and in detail. Unfractionated heparin is the oldest out of all and despite its simple action mechanism and adverse effects, is still a requested drug. Its lighter form, low-molecule-weight-heparin (LMWH) is an enhancement to the previous treatment due to its higher bioavailability and fewer side effects. Vitamin K antagonists (VKAs) are widely spread in medical environment thanks to their expanded mechanism of action, oral administration and reversibility of their overdose, as well as their well-developed anti-side effect therapy. Novel Oral Anticoagulants (NOACs) have been introduced to the market about 10 years ago. In spite of NOACs short period of clinical use, they were a huge change to the previous treating methods. Currently, the newest innovation in anticoagulant therapy are inhibitors of factor XI and its clinical trials outcome is promising for the future.Summary: The present article discusses history of anticoagulant drugs, their mechanism of action and usage but also focuses on the recent perspectives and developments as new anticoagulant drugs are being put to the test in therapeutic trials. The review underlines the importance of improvements in old therapeutic methods and exploring the new, more suitable ones.","PeriodicalId":15567,"journal":{"name":"Journal of Education, Health and Sport","volume":"63 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Education, Health and Sport","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12775/jehs.2024.68.49539","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Anticoagulants have been discovered and developed over past 100 years. At the beginning unfractionated heparin found its applications, just later to fade into the background of newer and more effective drugs. Patients have been treated with more progressive medications – Low-Molecule-Weight Heparin (LMWH), Vitamin K Antagonists (VKA) and Novel Oral Anticoagulants (NOAC). As for today, deemed a turning point in anticoagulant therapy are inhibitors of factor XI. It is a ground-breaking innovation as it ensures high prevention of thrombotic episodes and guarantees intact physiological hemostasis.Current State of Knowledge: The coagulation cascade and molecules part taking in that have been discovered and described extensively and in detail. Unfractionated heparin is the oldest out of all and despite its simple action mechanism and adverse effects, is still a requested drug. Its lighter form, low-molecule-weight-heparin (LMWH) is an enhancement to the previous treatment due to its higher bioavailability and fewer side effects. Vitamin K antagonists (VKAs) are widely spread in medical environment thanks to their expanded mechanism of action, oral administration and reversibility of their overdose, as well as their well-developed anti-side effect therapy. Novel Oral Anticoagulants (NOACs) have been introduced to the market about 10 years ago. In spite of NOACs short period of clinical use, they were a huge change to the previous treating methods. Currently, the newest innovation in anticoagulant therapy are inhibitors of factor XI and its clinical trials outcome is promising for the future.Summary: The present article discusses history of anticoagulant drugs, their mechanism of action and usage but also focuses on the recent perspectives and developments as new anticoagulant drugs are being put to the test in therapeutic trials. The review underlines the importance of improvements in old therapeutic methods and exploring the new, more suitable ones.
简介过去 100 年来,抗凝剂不断被发现和开发。起初,非分叶肝素(unfractionated heparin)被广泛应用,但后来逐渐被更新、更有效的药物所取代。患者一直在接受更先进的药物治疗--低分子肝素(LMWH)、维生素 K 拮抗剂(VKA)和新型口服抗凝剂(NOAC)。如今,被视为抗凝疗法转折点的是因子 XI 抑制剂。这是一项突破性创新,因为它能确保高度预防血栓发作,并保证完整的生理止血:凝血级联和参与凝血级联的分子已被广泛发现和详细描述。非减量肝素是所有药物中历史最悠久的一种,尽管其作用机制简单且有不良反应,但仍是一种常用药物。其较轻的形式--低分子重量肝素(LMWH)由于生物利用度高、副作用少,在以前的治疗基础上得到了加强。维生素 K 拮抗剂(VKA)因其作用机制更广、口服给药、过量可逆以及完善的抗副作用疗法而在医疗环境中广泛使用。新型口服抗凝药(NOACs)大约在 10 年前进入市场。尽管新型口服抗凝剂的临床应用时间不长,但它却极大地改变了以往的治疗方法。目前,抗凝疗法的最新创新是因子 XI 抑制剂,其临床试验结果令人对未来充满希望。摘要:本文讨论了抗凝药物的历史、作用机制和用法,但也重点关注了近期的前景和发展,因为新的抗凝药物正在治疗试验中接受考验。这篇综述强调了改进旧治疗方法和探索更合适的新方法的重要性。